BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
Pfizer stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
Investor's Business Daily on MSN9h
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHSModerna stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback